AUTHOR=Fazekas Franz , Bajenaru Ovidiu , Berger Thomas , Hojs Fabjan Tanja , Horvat Ledinek Alenka , Jakab Gábor , Komoly Samuel , Kobys Tetiana , Kraus Jörg , Kurča Egon , Kyriakides Theodore , Lisý Lubomír , Milanov Ivan , Moskovko Sergii , Nehrych Tetyana , Panayiotou Panayiotis , Sega Jazbec Sasa , Sokolova Larysa , Talab Radomir , Traykov Latchezar , Turčáni Peter , Vass Karl , Vella Norbert , Voloshyna Nataliya , Havrdova Eva TITLE=How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis? JOURNAL=Frontiers in Neurology VOLUME=4 YEAR=2013 URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2013.00010 DOI=10.3389/fneur.2013.00010 ISSN=1664-2295 ABSTRACT=

Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya®) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients.